AAX Biotech

AAX Biotech is developing new technologies to improve antibodies for therapy, the fastest growing segment in pharmaceuticals for more than 20 years. Seqitope is a new high-resolution, fast and efficient method for determining exactly where antibodies bind to the target protein, which accelerates the development of new antibodies. With Opti-mAb, we have developed a general method to stabilize antibodies, of great value in new cell-based cancer treatments such as CAR-T, but also for therapeutic bi-specific antibodies, and in diagnostics. In addition, a more efficient production, a more homogeneous product and fewer side effects are obtained during clinical use

Visit site